ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,487.03
0.25%
Dow Jones
38,834.86
0.15%
US Dollar vs MXN
18.40859
-0.03%
Brent Oil
84.645
-0.17%
Bitcoin
65,474.18
0.51%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. G1 Therapeutics Inc (GTHX)

  7. G1 Therapeutics Inc (GTHX) Noticias

GTHX G1 Therapeutics Inc

2.56
-0.11 (-4.12%)
18 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
G1 Therapeutics Inc GTHX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.11 -4.12% 2.56 23:00:06
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.69 2.54 2.69 2.56 2.67
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
14/6/202415:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202415:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202415:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202415:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/6/202415:08EDGAR2Form 8-K - Current report
05/6/202406:00GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
28/5/202405:30GLOBEMeaningful Improvement in Overall Survival (OS) and..
24/5/202415:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202416:06GLOBEG1 Therapeutics Announces Upcoming Presentation at the 2024..
22/5/202409:00GLOBEG1 Therapeutics to Participate in TD Cowen’s 5th Annual..
22/5/202405:30GLOBEG1 Therapeutics and Deimos Biosciences Announce Global..
15/5/202415:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/5/202415:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/5/202416:50GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
01/5/202405:30GLOBEG1 Therapeutics Provides First Quarter 2024 Financial..
01/5/202405:25GLOBEG1 Therapeutics and Pepper Bio Announce Global (Excluding..
17/4/202408:00GLOBEG1 Therapeutics to Release First Quarter 2024 Financial..
04/4/202409:30GLOBEG1 Therapeutics to Participate in the 23rd Annual Needham..
01/4/202415:20GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
01/3/202415:20GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
28/2/202405:35EDGAR2Form 8-K - Current report
28/2/202405:30GLOBEG1 Therapeutics Provides Fourth Quarter and Full Year 2023..
27/2/202407:30GLOBEG1 Therapeutics to Participate in the TD Cowen 44th Annual..
15/2/202407:30GLOBEG1 Therapeutics to Release Fourth Quarter and Full Year 2023..
13/2/202417:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202415:42EDGAR2Form 144 - Report of proposed sale of securities
12/2/202415:19EDGAR2Form 8-K - Current report
12/2/202415:05GLOBEG1 Therapeutics to Continue Pivotal Phase 3 Trial of..
09/1/202415:19EDGAR2Form 144 - Report of proposed sale of securities
08/1/202405:45GLOBEG1 Therapeutics Provides Corporate Update at the 42nd Annual..
08/1/202405:30EDGAR2Form 8-K - Current report
08/1/202405:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202405:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202405:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202405:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202405:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202405:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202408:00GLOBEG1 Therapeutics to Participate in the 42nd Annual J.P...
02/1/202418:44EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/1/202415:51GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
13/12/202315:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/12/202315:40EDGAR2Form 144 - Report of proposed sale of securities
11/12/202317:43EDGAR2Form 144 - Report of proposed sale of securities
05/12/202308:26GLOBEG1 Therapeutics Presents New Post Hoc Analyses Indicating..
01/12/202315:27GLOBEG1 Therapeutics Announces Inducement Grants Under Nasdaq..
29/11/202319:37GLOBEG1 Therapeutics Announces Upcoming Presentation at the 2023..
01/11/202315:37EDGAR2Form S-8 - Securities to be offered to employees in employee..

Su Consulta Reciente

NASDAQ
GTHX
G1 Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados